Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $26.36
• Market Cap: $1.91B
• P/E Ratio: 2.61
• EPS: $13.67
• 52-Week High: $44.60
• 52-Week Low: $6.11

Market Sentiment

Zenas BioPharma, Inc. Common Stock currently has a Bullish sentiment score of 0.19.

About Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing and commercializing innovative immunology-based therapies. With a strong focus on addressing unmet medical needs, Zenas boasts a robust pipeline aimed at treating autoimmune and rare diseases. The company utilizes proprietary technology platforms to create therapies that enhance immune responses, thereby improving patient outcomes and solidifying its position as...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Zenas BioPharma, Inc. Common Stock and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does ZBIO pay dividends?

Zenas BioPharma, Inc. Common Stock (ZBIO) does not currently pay a regular dividend.

What is ZBIO's P/E ratio?

Zenas BioPharma, Inc. Common Stock has a price-to-earnings (P/E) ratio of 2.61.

What is ZBIO's market cap?

Zenas BioPharma, Inc. Common Stock (ZBIO) has a market capitalization of $1.91B with a current stock price of $26.36.